Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Significant advancements have been made in the development of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates (ADC), and novel bispecific antibodies.

在开发针对HER2的治疗策略方面取得了重大进展，包括单克隆抗体、酪氨酸激酶抑制剂、抗体药物偶联物（ADC）和新型双特异性抗体。

These agents have revolutionized the treatment landscape for HER2-positive metastatic cancers, resulting in improved progression-free and overall survival, and quality of life for patients.

这些药物彻底改变了HER2阳性转移性癌症的治疗格局，带来了无进展生存期和总生存期的改善，以及患者生活质量的提升。

Beyond breast and gastric cancers, HER2 expression/amplification has been observed in other solid tumors, such as colorectal, lung, bladder, ovarian, and biliary tract cancers, offering new opportunities for personalized therapy in a larger patient population.

除了乳腺癌和胃癌之外，HER2表达/扩增也已在其他实体瘤中观察到，如结直肠癌、肺癌、膀胱癌、卵巢癌和胆道癌，为更大范围的患者群体提供了个性化治疗的新机会。

In this review, we highlight the current state of HER2-targeted treatment strategies across HER2-expressing solid tumors, discussing the clinical efficacy, adverse eventprofiles, and challenges of existing therapies.

在这篇综述中，我们强调了针对HER2表达的实体瘤的HER2靶向治疗策略的当前状态，讨论了现有疗法的临床疗效、不良事件特征以及面临的挑战。

We explore emerging treatment approaches, including novel agents such as HER2-targeting ADCs, combination therapies, and strategies to overcome resistance mechanisms.

我们探讨了新兴的治疗方法，包括新型药物如HER2靶向抗体偶联药物（ADCs）、联合治疗以及克服耐药机制的策略。

Additionally, we examine the role of HER2 expression heterogeneity, biomarker-driven patient selection, and diagnostic tools for patient selection and optimization of treatment outcomes.

此外，我们研究了HER2表达异质性、基于生物标志物的患者选择以及用于患者选择和治疗结果优化的诊断工具的作用。

This review also investigates ongoing challenges in expanding HER2-targeted therapies, including addressing intrinsic and acquired resistance and tailoring strategies to low HER2-expressing or HER2-mutant tumors.

此外，本综述还探讨了扩大HER2靶向治疗的持续挑战，包括解决固有和获得性耐药性，并针对低HER2表达或HER2突变肿瘤制定策略。

Lastly, we provide insights into future directions, emphasizing the importance of precision oncology to broaden the therapeutic opportunities of HER2-targeted therapies across diverse HER2-driven malignancies.

最后，我们提供了对未来方向的见解，强调了精准肿瘤学在扩大HER2靶向治疗在各种HER2驱动的恶性肿瘤治疗机会中的重要性。